

Figure 1: Dose dependent curve of SM17 binding to IL-17RB from different species




Figure 2: Binding specificity of SM17 to IL-17 receptor family members




Figure 3 SM17 binding to human native IL-17RB




Figure 4: Dose dependent inhibition of IL-5 by SM17 on human PBMC cultures




Figure 5: IL-8 production from TK-10 cells was inhibited by SM17




Figure 6: The effect of SM-17 in suppressing airway hyperresponsiveness of OVA-induced murine experimental asthma




Figure 7: The effect of SM-17 in suppressing BALF IL-5 and IL-13 levels in OVA-induced murine experimental asthma




Figure 8: The effect of SM-17 in suppressing BALF eosinophil cell counts in OVA-induced murine experimental asthma




Figure 9: Modes of IL25/SM17 interactions and possible disease indications




Figure 10A: The design of bispecific binding proteins (bispecific antibody and antibody-receptor fusion protein)




Figure 10B: Reducing SDS-PAGE of SM17, SM17-anti-TSLP, and SM17-anti-IL-33 bsBp purified from ExpiCHO transient transfection system




Figure 11: The antigen binding of anti-alarmin bispecific binding proteins




Figure 12: Induction of IFN γ , CCL8, CCL17, IL-5 and IL-13 from human PBMC by alarmins and the inhibitory effects of SM17 on cytokine release




Figure 13: Potencies of different bispecific binding proteins on cytokine and chemotactic factor releases from induced human PBMC




Figure 14: Pro-proliferative effects of alarmins on ILC2s




Figure 15: Results of the response of ILC2s and Th2 cells to steroid hormone




Figure 16: Results of dendritic cell potency assay

